Literature DB >> 25139069

The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder.

Roman Mayr1, Matthias May, Maximilian Burger, Thomas Martini, Armin Pycha, Christopher Dechet, Michele Lodde, Evi Comploj, Wolf F Wieland, Stefan Denzinger, Wolfgang Otto, Atiqullah Aziz, Hans-Martin Fritsche, Michael Gierth.   

Abstract

OBJECTIVE: To identify prognostic clinical and histopathological parameters, including comorbidity indices at the time of radical cystectomy (RC), for overall survival (OS) after recurrence following RC for urothelial carcinoma of the bladder (UCB).
MATERIALS AND METHODS: A retrospective multicenter study was carried out in 555 unselected consecutive patients who underwent RC with pelvic lymph node dissection for UCB from 2000 to 2010. A total of 227 patients with recurrence comprised our study group. Cox proportional hazards regression models were calculated with established variables to assess their independent influence on OS after recurrence.
RESULTS: The median time from RC to recurrence and the median OS after recurrence was 10.9 and 5.4 months, respectively. Neither the time to recurrence nor the type of recurrence (systematic vs. local) was predictive of the OS. In contrast, age (hazard ratio (HR) 1.53, p = 0.011), lymph node metastasis (HR 1.56, p = 0.007), and positive surgical margins (HR 1.53, p = 0.046) significantly affected the OS after disease recurrence. In addition, the dichotomized Charlson comorbidity index (CCI; dichotomized into >2 vs. 0-2) was the only comorbidity score with an independent prediction of OS (HR 1.41, p = 0.033). We observed a significant gain in the base model's predictive accuracy, i.e. from 68.4 to 70.3% (p < 0.001), after inclusion of the dichotomized CCI.
CONCLUSIONS: We present the first outcome study of comorbidity indices used as predictors of OS after disease recurrence in patients undergoing RC for UCB. The CCI at the time of RC had no significant influence on the time to recurrence but represented an independent predictor of OS after disease recurrence. 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25139069     DOI: 10.1159/000362421

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  8 in total

1.  Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Authors:  Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann
Journal:  Eur Urol Oncol       Date:  2018-06-06

2.  Validity of the age-adjusted charlson comorbidity index on clinical outcomes for patients with nasopharyngeal cancer post radiation treatment: a 5-year nationwide cohort study.

Authors:  Ching-Chieh Yang; Po-Chun Chen; Chia-Wen Hsu; Shih-Lun Chang; Ching-Chih Lee
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

Review 3.  Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.

Authors:  Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat
Journal:  World J Urol       Date:  2017-11-16       Impact factor: 4.226

4.  Different models for prediction of radical cystectomy postoperative complications and care pathways.

Authors:  Jacob Taylor; Xiaosong Meng; Audrey Renson; Angela B Smith; James S Wysock; Samir S Taneja; William C Huang; Marc A Bjurlin
Journal:  Ther Adv Urol       Date:  2019-09-19

5.  Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.

Authors:  Harriet P Mintz; Amandeep Dosanjh; Helen M Parsons; Ana Hughes; Alicia Jakeman; Ann M Pope; Richard T Bryan; Nicholas D James; Prashant Patel
Journal:  Pilot Feasibility Stud       Date:  2020-10-31

6.  Age-adjusted Charlson Comorbidity Index: A Simple Tool, but Needs Further Validation in COVID-19 Patients.

Authors:  Velmurugan Selvam; Shrikanth Srinivasan
Journal:  Indian J Crit Care Med       Date:  2021-09

7.  Prognosis models for severe and critical COVID-19 based on the Charlson and Elixhauser comorbidity indices.

Authors:  Wei Zhou; Xiaoyi Qin; Xiang Hu; Yingru Lu; Jingye Pan
Journal:  Int J Med Sci       Date:  2020-08-25       Impact factor: 3.738

8.  Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?

Authors:  Melanie Barz; Stefanie Bette; Insa Janssen; A Kaywan Aftahy; Thomas Huber; Friederike Liesche-Starnecker; Yu-Mi Ryang; Benedikt Wiestler; Stephanie E Combs; Bernhard Meyer; Jens Gempt
Journal:  BMC Neurol       Date:  2022-01-21       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.